<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Holstege, J.</title>
    <link>http://repub.eur.nl/res/aut/5596/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Differential distribution of activated spinal neurons containing glycine and/or GABA and expressing c-fos in acute and chronic pain models (Article)</title>
      <link>http://repub.eur.nl/res/pub/20973/</link>
      <pubDate>2010-11-01T00:00:00Z</pubDate>
      <description>The inhibitory transmitters GABA and glycine play an important role in modulating pain transmission, both in normal and in pathological situations. In the present study we have combined in situ hybridization for identifying spinal neurons that use the transmitter(s) glycine and/or GABA (Gly/GABA neurons) with immunohistochemistry for c-fos, a marker for neuronal activation. This procedure was used with acute pain models induced by the injection of capsaicin or formalin; and chronic pain models using Complete Freund's Adjuvant (CFA, chronic inflammation), and the spared nerve injury (SNI) model (neuropathic pain). In all models Gly/GABA neurons were activated as indicated by their expression of c-fos. The pattern of Gly/GABA neuronal activation was different for every model, both anatomically and quantitatively. However, the averaged percentage of activated neurons that were Gly/GABA in the chronic phase (≥20 h survival, 46%) was significantly higher than in the acute phase (≤2 h survival, 34%). In addition, the total numbers of activated Gly/GABA neurons were similar in both phases, showing that the activation of non-Gly/GABA (presumed excitatory) neurons in the chronic phase decreased. Finally, morphine application equally decreased the total number of activated neurons and activated Gly/GABA neurons. This showed that morphine did not specifically activate Gly/GABA neurons to achieve nociceptive inhibition. The present study shows an increased activity of Gly/GABA neurons in acute and chronic models. This mechanism, together with mechanisms that antagonize the effects of GABA and glycine at the receptor level, may determine the sensitivity of our pain system during health and disease.</description>
    </item> <item>
      <title>The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome (Article)</title>
      <link>http://repub.eur.nl/res/pub/10126/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>Recent studies have reported that alleles in the premutation range in the
      FMR1 gene in males result in increased FMR1 mRNA levels and at the same
      time mildly reduced FMR1 protein levels. Some elderly males with
      premutations exhibit an unique neurodegenerative syndrome characterized by
      progressive intention tremor and ataxia. We describe neurohistological,
      biochemical and molecular studies of the brains of mice with an expanded
      CGG repeat and report elevated Fmr1 mRNA levels and intranuclear
      inclusions with ubiquitin, Hsp40 and the 20S catalytic core complex of the
      proteasome as constituents. An increase was observed of both the number
      and the size of the inclusions during the course of life, which correlates
      with the progressive character of the cerebellar tremor/ataxia syndrome in
      humans. The observations in expanded-repeat mice support a direct role of
      the Fmr1 gene, by either CGG expansion per se or by mRNA level, in the
      formation of the inclusions and suggest a correlation between the presence
      of intranuclear inclusions in distinct regions of the brain and the
      clinical features in symptomatic premutation carriers. This mouse model
      will facilitate the possibilities to perform studies at the molecular
      level from onset of symptoms until the final stage of the disease.</description>
    </item>
  </channel>
</rss>